DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer

References

• Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3:673-82; PMID:8777713; http://dx.doi.org/10.1016/1074-7613(95)90057-8
   PubMed Web of Science ®Google Scholar
• Mohr A, Henderson G, Dudus L, Herr I, Kuerschner T, Debatin KM, Weiher H, Fisher KJ, Zwacka RM. AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression. Gene Ther 2004; 11:534-43; PMID:14999225; http://dx.doi.org/10.1038/sj.gt.3302154
   PubMed Web of Science ®Google Scholar
• Mohr A, Lyons M, Deedigan L, Harte T, Shaw G, Howard L, Barry F, O'Brien T, Zwacka R. Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. J Cell Mol Med 2008; 12:2628-43; PMID:18373740; http://dx.doi.org/10.1111/j.1582-4934.2008.00317.x
   PubMed Web of Science ®Google Scholar
• Testa U. TRAILTRAIL-R in hematologic malignancies. J Cell Biochem 2010; 110:21-34; PMID:20336667
   PubMed Web of Science ®Google Scholar
• Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271:12687-90; PMID:8663110; http://dx.doi.org/10.1074/jbc.271.22.12687
   PubMed Web of Science ®Google Scholar
• Cha SS, Kim MS, Choi YH, Sung BJ, Shin NK, Shin HC, Sung YC, Oh BH. 2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity 1999; 11:253-61; PMID:10485660; http://dx.doi.org/10.1016/S1074-7613(00)80100-4
   PubMed Web of Science ®Google Scholar
• Hymowitz SG, O’Connell MP, Ultsch MH, Hurst A, Totpal K, Ashkenazi A, de Vos AM, Kelley RF. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2LTRAIL. Biochem (Mosc) 2000; 39:633-40; PMID:10651627; http://dx.doi.org/10.1021/bi992242l
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104:155-62; PMID:10411544; http://dx.doi.org/10.1172/JCI6926
   PubMed Web of Science ®Google Scholar
• LeBlanc HN, Ashkenazi A. Apo2LTRAIL and its death and decoy receptors. Cell Death Differ 2003; 10:66-75; PMID:12655296; http://dx.doi.org/10.1038/sj.cdd.4401187
   PubMed Web of Science ®Google Scholar
• Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, Blenis J, Tschopp J. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000; 2:241-3; PMID:10783243; http://dx.doi.org/10.1038/35008667
   PubMed Web of Science ®Google Scholar
• Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2LTRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000; 12:611-20; PMID:10894161; http://dx.doi.org/10.1016/S1074-7613(00)80212-5
   PubMed Web of Science ®Google Scholar
• Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH, Walczak H. FADDMORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000; 12:599-609; PMID:10894160; http://dx.doi.org/10.1016/S1074-7613(00)80211-3
   PubMed Web of Science ®Google Scholar
• Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277:818-21; PMID:9242611; http://dx.doi.org/10.1126/science.277.5327.818
   PubMed Web of Science ®Google Scholar
• Kimberley FC, Screaton GR. Following a TRAIL: update on a ligand and its five receptors. Cell Res 2004; 14:359-72; PMID:15538968; http://dx.doi.org/10.1038/sj.cr.7290236
   PubMed Web of Science ®Google Scholar
• Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 2006; 26:7046-55; PMID:16980609; http://dx.doi.org/10.1128/MCB.00520-06
   PubMed Web of Science ®Google Scholar
• Leibbrandt A, Penninger JM. RANKLRANK as key factors for osteoclast development and bone loss in arthropathies. Adv Exp Med Biol 2009; 649:100-13; PMID:19731623; http://dx.doi.org/10.1007/978-1-4419-0298-6_7
   PubMed Web of Science ®Google Scholar
• Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273:14363-7; PMID:9603945; http://dx.doi.org/10.1074/jbc.273.23.14363
   PubMed Web of Science ®Google Scholar
• Vindrieux D, Reveiller M, Chantepie J, Yakoub S, Deschildre C, Ruffion A, Devonec M, Benahmed M, Grataroli R. Down-regulation of DcR2 sensitizes androgen-dependent prostate cancer LNCaP cells to TRAIL-induced apoptosis. Cancer Cell Int 2011; 11:42; PMID:22136382; http://dx.doi.org/10.1186/1475-2867-11-42
   PubMed Web of Science ®Google Scholar
• Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, Ing J, Tohnya TM, Sager J, Ashkenazi A, et al. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res 2010; 16:1256-63; PMID:20145186; http://dx.doi.org/10.1158/1078-0432.CCR-09-1267
   PubMed Web of Science ®Google Scholar
• Chuntharapai A, Dodge K, Grimmer K, Schroeder K, Marsters SA, Koeppen H, Ashkenazi A, Kim KJ. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 2001; 166:4891-8; PMID:11290766; http://dx.doi.org/10.4049/jimmunol.166.8.4891
   PubMed Web of Science ®Google Scholar
• Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001; 7:954-60; PMID:11479629; http://dx.doi.org/10.1038/91000
   PubMed Web of Science ®Google Scholar
• Trarbach T, Moehler M, Heinemann V, Kohne CH, Przyborek M, Schulz C, Sneller V, Gallant G, Kanzler S. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer 2010; 102:506-12; PMID:20068564; http://dx.doi.org/10.1038/sj.bjc.6605507
   PubMed Web of Science ®Google Scholar
• MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res 2005; 65:11265-70; PMID:16357130; http://dx.doi.org/10.1158/0008-5472.CAN-05-2801
   PubMed Web of Science ®Google Scholar
• van der Sloot AM, Tur V, Szegezdi E, Mullally MM, Cool RH, Samali A, Serrano L, Quax WJ. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci U S A 2006; 103:8634-9; PMID:16731632; http://dx.doi.org/10.1073/pnas.0510187103
   PubMed Web of Science ®Google Scholar
• Duiker EW, de Vries EG, Mahalingam D, Meersma GJ, Boersma-van Ek W, Hollema H, Lub-de Hooge MN, van Dam GM, Cool RH, Quax WJ, et al. Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model. Clin Cancer Res 2009; 15:2048-57; PMID:19276284; http://dx.doi.org/10.1158/1078-0432.CCR-08-1535
   PubMed Web of Science ®Google Scholar
• Reis CR, van der Sloot AM, Natoni A, Szegezdi E, Setroikromo R, Meijer M, Sjollema K, Stricher F, Cool RH, Samali A, et al. Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants. Cell Death Dis 2010; 1:e83; PMID:21368856; http://dx.doi.org/10.1038/cddis.2010.61
   PubMedGoogle Scholar
• Yu R, Deedigan L, Albarenque SM, Mohr A, Zwacka RM. Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects. Cell Death Dis 2013; 4:e503; PMID:23429289; http://dx.doi.org/10.1038/cddis.2013.19
   PubMed Web of Science ®Google Scholar
• Tur V, van der Sloot AM, Reis CR, Szegezdi E, Cool RH, Samali A, Serrano L, Quax WJ. DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design. J Biol Chem 2008; 283:20560-8; PMID:18474604; http://dx.doi.org/10.1074/jbc.M800457200
   PubMed Web of Science ®Google Scholar
• Reis CR, van der Sloot AM, Szegezdi E, Natoni A, Tur V, Cool RH, Samali A, Serrano L, Quax WJ. Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors. Biochem (Mosc) 2009; 48:2180-91; PMID:19236007; http://dx.doi.org/10.1021/bi801927x
   PubMed Web of Science ®Google Scholar
• Szegezdi E, Reis CR, van der Sloot AM, Natoni A, O’Reilly A, Reeve J, Cool RH, O'Dwyer M, Knapper S, Serrano L, et al. Targeting AML through DR4 with a novel variant of rhTRAIL. J Cell Mol Med 2011; 15:2216-31; PMID:21070598; http://dx.doi.org/10.1111/j.1582-4934.2010.01211.x
   PubMed Web of Science ®Google Scholar
• Szegezdi E, van der Sloot AM, Mahalingam D, O’Leary L, Cool RH, Munoz IG, Montoya G, Quax WJ, de Jong S, Samali A, et al. Kinetics in signal transduction pathways involving promiscuous oligomerizing receptors can be determined by receptor specificity: apoptosis induction by TRAIL. Mol Cell Proteomics 2012; 11:M111 013730; PMID:22213832; http://dx.doi.org/10.1074/mcp.M111.013730
   PubMedGoogle Scholar
• Lemke J, Noack A, Adam D, Tchikov V, Bertsch U, Roder C, Schütze S, Wajant H, Kalthoff H, Trauzold A. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5. J Mol Med 2010; 88:729-40; PMID:20354842; http://dx.doi.org/10.1007/s00109-010-0619-0
   PubMed Web of Science ®Google Scholar
• Stadel D, Mohr A, Ref C, MacFarlane M, Zhou S, Humphreys R, Bachem M, Cohen G, Möller P, Zwacka RM, et al. TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors. Clin Cancer Res 2010; 16:5734-49; PMID:20940278; http://dx.doi.org/10.1158/1078-0432.CCR-10-0985
   PubMed Web of Science ®Google Scholar
• Kim MH, Billiar TR, Seol DW. The secretable form of trimeric TRAIL, a potent inducer of apoptosis. Biochem Biophys Res Commun 2004; 321:930-5; PMID:15358116; http://dx.doi.org/10.1016/j.bbrc.2004.07.046
   PubMed Web of Science ®Google Scholar
• Mohr A, Albarenque SM, Deedigan L, Yu R, Reidy M, Fulda S, Zwacka RM. Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells. Stem Cells 2010; 28:2109-20; PMID:20882532; http://dx.doi.org/10.1002/stem.533
   PubMed Web of Science ®Google Scholar
• Wajant H, Moosmayer D, Wuest T, Bartke T, Gerlach E, Schonherr U, Peters N, Scheurich P, Pfizenmaier K. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 2001; 20:4101-6; PMID:11494138; http://dx.doi.org/10.1038/sj.onc.1204558
   PubMed Web of Science ®Google Scholar
• Reis CR, van Assen AH, Quax WJ, Cool RH. Unraveling the binding mechanism of trivalent tumor necrosis factor ligands and their receptors. Mol Cell Proteomics 2011; 10:M110 002808; PMID:20852190; http://dx.doi.org/10.1074/mcp.M110.002808
   PubMedGoogle Scholar
• Fulda S, Debatin KM. Modulation of TRAIL signaling for cancer therapy. Vitam Horm 2004; 67:275-90; PMID:15110182; http://dx.doi.org/10.1016/S0083-6729(04)67015-4
   PubMed Web of Science ®Google Scholar
• Braeuer SJ, Buneker C, Mohr A, Zwacka RM. Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells. Mol Cancer Res 2006; 4:715-28; PMID:17050666; http://dx.doi.org/10.1158/1541-7786.MCR-05-0231
   PubMed Web of Science ®Google Scholar
• Khanbolooki S, Nawrocki ST, Arumugam T, Andtbacka R, Pino MS, Kurzrock R, Logsdon CD, Abbruzzese JL, McConkey DJ. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther 2006; 5:2251-60; PMID:16985059; http://dx.doi.org/10.1158/1535-7163.MCT-06-0075
   PubMed Web of Science ®Google Scholar
• Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005; 12:228-37; PMID:15550937; http://dx.doi.org/10.1038/sj.cgt.7700792
   PubMed Web of Science ®Google Scholar
• Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, Borden EC. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2LTRAIL-induced apoptosis. Cell Death Differ 2004; 11:915-23; PMID:15118763; http://dx.doi.org/10.1038/sj.cdd.4401416
   PubMed Web of Science ®Google Scholar
• Vogler M, Durr K, Jovanovic M, Debatin KM, Fulda S. Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene 2007; 26:248-57; PMID:16832350; http://dx.doi.org/10.1038/sj.onc.1209776
   PubMed Web of Science ®Google Scholar
• Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, Bhanot U, Hasel C, Möller P, Gschwend JE, et al. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 2009; 69:2425-34; PMID:19258513; http://dx.doi.org/10.1158/0008-5472.CAN-08-2436
   PubMed Web of Science ®Google Scholar
• Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, Gschwend JE, Simmet T, Debatin KM, Fulda S. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res 2008; 68:7956-65; PMID:18829553; http://dx.doi.org/10.1158/0008-5472.CAN-08-1296
   PubMed Web of Science ®Google Scholar
• Hinz S, Trauzold A, Boenicke L, Sandberg C, Beckmann S, Bayer E, Walczak H, Kalthoff H, Ungefroren H. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 2000; 19:5477-86; PMID:11114725; http://dx.doi.org/10.1038/sj.onc.1203936
   PubMed Web of Science ®Google Scholar
• Leverkus M, Neumann M, Mengling T, Rauch CT, Brocker EB, Krammer PH, Walczak H. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 2000; 60:553-9; PMID:10676636
   PubMed Web of Science ®Google Scholar
• Siegmund D, Hadwiger P, Pfizenmaier K, Vornlocher HP, Wajant H. Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis. Mol Med 2002; 8:725-32; PMID:12520089
   PubMed Web of Science ®Google Scholar
• Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC, Krueger A, Weigand MA, Grosse-Wilde A, Stremmel W, et al. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 2004; 11 Suppl 1:S86-96; PMID:15105837; http://dx.doi.org/10.1038/sj.cdd.4401437
   PubMedGoogle Scholar
• Buneker CK, Yu R, Deedigan L, Mohr A, Zwacka RM. IFN-gamma combined with targeting of XIAP leads to increased apoptosis-sensitisation of TRAIL resistant pancreatic carcinoma cells. Cancer Lett 2012; 316:168-77; PMID:22104728; http://dx.doi.org/10.1016/j.canlet.2011.10.035
   PubMed Web of Science ®Google Scholar
• Leverkus M, Sprick MR, Wachter T, Denk A, Brocker EB, Walczak H, Neumann M. TRAIL-induced apoptosis and gene induction in HaCaT keratinocytes: differential contribution of TRAIL receptors 1 and 2. J Invest Dermatol 2003; 121:149-55; PMID:12839575; http://dx.doi.org/10.1046/j.1523-1747.2003.12332.x
   PubMed Web of Science ®Google Scholar
• Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, DeForge L, Pai R, Hymowitz SG, Ashkenazi A. Receptor-selective mutants of apoptosis-inducing ligand 2tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 2005; 280:2205-12; PMID:15520016; http://dx.doi.org/10.1074/jbc.M410660200
   PubMed Web of Science ®Google Scholar
• van Geelen CM, Pennarun B, Le PT, de Vries EG, de Jong S. Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5. BMC Cancer 2011; 11:39; PMID:21272366; http://dx.doi.org/10.1186/1471-2407-11-39
   PubMed Web of Science ®Google Scholar
• Kim CY, Jeong M, Mushiake H, Kim BM, Kim WB, Ko JP, Kim MH, Kim M, Kim TH, Robbins PD, et al. Cancer gene therapy using a novel secretable trimeric TRAIL. Gene Ther 2006; 13:330-8; PMID:16195699; http://dx.doi.org/10.1038/sj.gt.3302658
   PubMed Web of Science ®Google Scholar
• Kim SM, Lim JY, Park SI, Jeong CH, Oh JH, Jeong M, Oh W, Park SH, Sung YC, Jeun SS. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 2008; 68:9614-23; PMID:19047138; http://dx.doi.org/10.1158/0008-5472.CAN-08-0451
   PubMed Web of Science ®Google Scholar
• Menon LG, Kelly K, Yang HW, Kim SK, Black PM, Carroll RS. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells 2009; 27:2320-30; PMID:19544410; http://dx.doi.org/10.1002/stem.136
   PubMed Web of Science ®Google Scholar
• McCullum EO, Williams BA, Zhang J, Chaput JC. Random mutagenesis by error-prone PCR. Methods Mol Biol 2010; 634:103-9; PMID:20676978; http://dx.doi.org/10.1007/978-1-60761-652-8_7
   PubMedGoogle Scholar
• Loebinger MR, Eddaoudi A, Davies D, Janes SM. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 2009; 69:4134-42; PMID:19435900; http://dx.doi.org/10.1158/0008-5472.CAN-08-4698
   PubMed Web of Science ®Google Scholar
• Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139:271-9; PMID:1710634; http://dx.doi.org/10.1016/0022-1759(91)90198-O
   PubMed Web of Science ®Google Scholar
• Mohr A, Buneker C, Gough RP, Zwacka RM. MnSOD protects colorectal cancer cells from TRAIL-induced apoptosis by inhibition of SmacDIABLO release. Oncogene 2008; 27:763-74; PMID:17653087; http://dx.doi.org/10.1038/sj.onc.1210673
   PubMed Web of Science ®Google Scholar
• Zwacka RM, Stark L, Dunlop MG. NF-kappaB kinetics predetermine TNF-alpha sensitivity of colorectal cancer cells. J Gene Med 2000; 2:334-43; PMID:11045427; http://dx.doi.org/10.1002/1521-2254(200009/10)2:5%3c334::AID-JGM129%3e3.0.CO;2-Q
   PubMed Web of Science ®Google Scholar